Natural Capsules Ltd.

305.50 +0.25 ▲0.1%

28 March 2024, 04:01:00 PM
Volume: 26,755

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.naturalcapsules.com
Market Cap 285.61 Cr.
Enterprise Value(EV) 367.42 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 7.75 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 39.40 Trailing Twelve Months Ending 2023-12
Industry PE 41.54 Trailing Twelve Months Ending 2023-12
Book Value / Share 136.32 Trailing Twelve Months Ending 2023-12
Price to Book Value 2.24 Calculated using Price: 305.50
Dividend Yield 0.33 Period Ending 2023-03
No. of Shares Subscribed 0.93 Cr. 9,349,050 Shares
FaceValue 10
About Natural Capsules Ltd.
Natural Capsules is a public limited company established in the year 1993.The company is a well-equipped modern manufacturing plant to manufacture hard gelatin capsule shells, Hard cellulose capsule shells and pharmaceutical dosage forms in capsule dosage form.

Natural Capsules Ltd. Delivery

Delivered Qty
Traded Qty

Natural Capsules Ltd. Performance

1 Day
+0.08%
1 Week
-4.68%
1 Month
-7.52%
3 Month
-15.09%
6 Month
-21.01%
1 Year
-22.00%
2 Year
-30.14%
5 Year
+489.54%
10 Year
+1028.97%

Natural Capsules Ltd. Fundamental Ratios

6 years 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 2.05 3.5 1.54 11.74 19.18 17.89
Return on Capital Employed (%) 3.71 4.51 3.71 14.52 20.75 16.18
Return on Assets (%) 1.56 2.66 1.16 8.05 10.65 8.14

Natural Capsules Ltd. Balance Sheet

Particulars 7 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 54 55 56 62 83 123 126
Non Curr. Liab. 2 1 1 2 37 74 68
Curr. Liab. 15 16 18 33 45 67 73
Minority Int. 25 75
Equity & Liab. 71 73 75 97 164 289 342
Non Curr. Assets 29 35 37 47 89 187 218
Curr. Assets 42 38 38 50 76 102 124
Misc. Exp. not W/O
Total Assets 71 73 75 97 164 289 342

Natural Capsules Ltd. Profit and Loss

Particulars 7 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 55 60 62 80 135 172 153
Other Income 1 1 1 1 2 2 1
Total Income 56 61 63 80 137 174 154
Total Expenditure -49 -55 -56 -68 -111 -138 -130
PBIDT 6 6 6 12 27 36 24
Interest 0 -1 -1 -1 -2 -4 -5
Depreciation -4 -3 -4 -4 -5 -7 -8
Taxation -1 0 -1 -2 -5 -7 -3
Exceptional Items 0 2
PAT 1 2 1 7 14 18 7
Minority Interest
Share Associate
Other Related Items 0 0 0
Consolidated Net Profit 1 2 1 7 14 18 7
Adjusted EPS 1 3 1 9 20 20 8

Natural Capsules Ltd. Cash Flow

Particulars 6 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 5 2 7 6 -1 17
Cash Fr. Inv. -1 -7 -6 -9 -46 -105
Cash Fr. Finan. -4 4 -1 3 48 87
Net Change 0 -1 0 0 1 0
Cash & Cash Eqvt 1 0 0 0 1 1

Natural Capsules Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 56.58 56.57 56.57 56.56 56.56 56.56 56.56 56.56 56.56
Public 43.42 43.43 43.43 43.44 43.44 43.44 43.44 43.44 43.44
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Natural Capsules Ltd. Announcements

Wed, 27 Mar 2024
Closure of Trading Window
Pursuant to SEBI (PIT) Regulations 2015 and companys code of conduct for prevention of Insider Trading and code of corporate disclosure practices we wish to inform that the Trading window for dealing in the equity shares of the Company shall remain closed for all Designated Persons and their immediate relative with effect from 01.04.2024 till the conclusion of 48 hours after the declaration of financial results of the company for the period ended 31.03.2024. The date of Board Meeting of the Company for declaration of financial results shall be intimated in due course.
Mon, 18 Mar 2024
Announcement Under Regulation 30 (LODR)-Commencement Of Commercial Production In High Speed HPMC Line
Pursuant to the provisions of Regulation 30 of SEBI (LODR) we wish to inform you that the Company has initiated production in the first high speed HPMC line on 18.03.2024. Upon reaching full operational capacity the company will proceed with commercialization in second and third high speed HPMC lines.
Fri, 15 Mar 2024
Announcement Under Regulation 30 (LODR)-Commencement Of Production Of Small Volume Batches Of Natural Biogenex Private Limited Subsidiary Of The Company
Pursuant to the provisions of Regulation 30 of SEBI (LODR) We wish to inform you that M/S Natural Biogenex Private Limited Subsidiary of the Company has commenced production of small volume batches on 15th March 2024.

Natural Capsules Ltd. Technical Scans

Thu, 28 Mar 2024
High Delivery Percentage High Delivery Percentage
Opening at High Opening at High
Making Lower Lows for 3 days Making Lower Lows for 3 days
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
Close Below Last Month Low Close Below Last Month Low

Natural Capsules Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 388,812.23 1,620.50 +0.8%
Cipla Ltd. 120,673.12 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. 102,679.14 6,171.85 +2.0%
Zydus Lifesciences Ltd. 101,151.67 1,007.35 +0.8%
Mankind Pharma Ltd. 92,029.19 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. 91,330.58 6,347.35 +1.9%
Divi's Laboratories Ltd. 91,234.91 3,452.55 +2.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 43.66 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-12 32.54 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 19.64 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 34.01 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-12 53.29 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 115.71 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-12 65.97 3,452.55 +2.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 6.23 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-12 4.66 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.82 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.37 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-12 10.36 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.52 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-12 7.00 3,452.55 +2.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 0.02 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,452.55 +2.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 12.85 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,452.55 +2.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 12.85 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,452.55 +2.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,452.55 +2.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,452.55 +2.6%

Natural Capsules Ltd. FAQ's

What is Natural Capsules share price?

Can I buy Natural Capsules shares now?

What is the Dividend Yield of Natural Capsules?

What is the Market Cap of Natural Capsules?

What are the key metrics to analyse Natural Capsules?

What is the 52 Week High and Low of Natural Capsules?

What is the trend of Natural Capsules share price?